^
Association details:
| Biomarker: | FAP overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer
Published date:
08/11/2022
Excerpt:
A total of 135 patients with advanced NSCLC who received PD-1 blockade therapy were retrospectively analyzed....The patients with higher expression of FAP showed worse response rate (16.4% vs. 38.7%, p < 0.001) and worse progression-free survival (HR = 2.56, 95% CI 1.69-3.87, p < 0.001). In addition, FAP contributed to shortened overall survival in subgroups of the patients with squamous cell lung cancer (p = 0.020), PD-1 blockade monotherapy (p = 0.017), and first-line therapy (p = 0.028)....FAP is a potential predictive biomarker of resistance to PD-1 blockade.
DOI:
10.1007/s00432-022-04250-4
